DE216901T1 - IMMUNOGENIC ANTIGEN-CARRIER PROTEIN CONJUGATE FOR USE IN VACCINE AGAINST MALARIA. - Google Patents

IMMUNOGENIC ANTIGEN-CARRIER PROTEIN CONJUGATE FOR USE IN VACCINE AGAINST MALARIA.

Info

Publication number
DE216901T1
DE216901T1 DE1986902613 DE86902613T DE216901T1 DE 216901 T1 DE216901 T1 DE 216901T1 DE 1986902613 DE1986902613 DE 1986902613 DE 86902613 T DE86902613 T DE 86902613T DE 216901 T1 DE216901 T1 DE 216901T1
Authority
DE
Germany
Prior art keywords
asn
conjugate
pro
ala
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1986902613
Other languages
German (de)
Inventor
N. Victor New York Ny 10012 Nussenzweig
P. Fidel New York Ny 10028 Zavala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Priority claimed from PCT/US1986/000627 external-priority patent/WO1986005790A1/en
Publication of DE216901T1 publication Critical patent/DE216901T1/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (26)

021G901 902 613.8 New York University Patentansprüche021G901 902 613.8 New York University Patent Claims 1. Konjugat eines immunogenen Peptids, wobei das Peptid eine Aminosäuresequenz besitzt, die der eines immunodominanten Epitops des P.falciparum Circumsporozoit-Proteins entspricht, und eines Trägerproteins, gewählt aus der Gruppe, bestehend aus Trägerproteinen, die in Vakzinherstellungen verwendet werden.1. A conjugate of an immunogenic peptide, the peptide having an amino acid sequence corresponding to that of an immunodominant epitope of the P.falciparum circumsporozoite protein, and a carrier protein selected from the group consisting of carrier proteins used in vaccine preparations. 2. Konjugat nach Anspruch 1, worin das Epitop im wesentlichen aus einer tandemartigen Wiederholung der Aminosäuresequenz Asn-Ala-Asn-Pro besteht.2. Conjugate according to claim 1, wherein the epitope consists essentially of a tandem repetition of the amino acid sequence Asn-Ala-Asn-Pro. 3. Konjugat nach Anspruch 2, worin das Peptid chemisch synthetisiert worden ist.3. A conjugate according to claim 2, wherein the peptide has been chemically synthesized. 4. Konjugat nach Anspruch 3, worin das Peptid die Aminosäuresequenz Asn-Al a-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro besitzt.4. The conjugate of claim 3, wherein the peptide has the amino acid sequence Asn-Al a-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro . 5. Konjugat nach Anspruch 1, worin das Trägerprotein aus der Gruppe, bestehend aus Diphtherietoxoid, Tetanustoxoid und synthetischen Zufallscopolymeren von Aminosäuren, enthaltend Lysin oder Arginin oder Kombinationen daraus, gewählt wird.5. The conjugate of claim 1, wherein the carrier protein is selected from the group consisting of diphtheria toxoid, tetanus toxoid and synthetic random copolymers of amino acids, containing lysine or arginine or combinations thereof. 6. Konjugat nach Anspruch 4, worin das Protein Tetanustoxoid ist.6. The conjugate of claim 4, wherein the protein is tetanus toxoid. 7. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 1.7. Vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 1. 8. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 2.8. Vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 2. 9. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 4.9. Vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 4. 10· Vakzinkomponente gegen Malaria, bestehend im wesentlichen aus dem Konjugat nach Anspruch 6.10· Vaccine component against malaria, consisting essentially of the conjugate according to claim 6. 11. Konjugat nach Anspruch 4, worin das Epitop im wesentlichen aus einer tandemartigen Wiederholung der Aminosäuresequenz Asn-Ala-Asn-Pro von dem Carboxyl terminus bis zum Aminoterminus besteht.11. The conjugate of claim 4, wherein the epitope consists essentially of a tandem repeat of the amino acid sequence Asn-Ala-Asn-Pro from the carboxyl terminus to the amino terminus. 12. Konjugat nach Anspruch 11, worin das Peptid chemisch synthetisiert worden ist.12. The conjugate of claim 11, wherein the peptide has been chemically synthesized. 13. Konjugat nach Anspruch 4, worin das Peptid die Aminosäuresequenz Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro von dem Aminoterminus bis zum Carboxyl terminus besitzt.13. The conjugate of claim 4, wherein the peptide has the amino acid sequence Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro from the amino terminus to the carboxyl terminus. 14. Konjugat nach Anspruch 13, worin das Protein Tetanustoxoid ist.14. The conjugate of claim 13, wherein the protein is tetanus toxoid. 15. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 11.15. Vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 11. 3Q 16. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 13.3Q 16. Vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 13. 17. Vakzinkomponente gegen Malaria, bestehend im wesentlichen aus dem Konjugat nach Anspruch 14.17. A vaccine component against malaria, consisting essentially of the conjugate according to claim 14. 18. Konjugat nach Anspruch 11, worin das Peptid die Sequenz18. Conjugate according to claim 11, wherein the peptide has the sequence Cys-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-ProCys-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro von dem Aminoterminus bis zum CarboxyHerminus besitzt.from the amino terminus to the carboxy terminus. 19. Konjugat nach Anspruch 18, worin das Peptid chemisch synthetisiert worden ist.19. The conjugate of claim 18, wherein the peptide has been chemically synthesized. 20. Konjugat nach Anspruch 11, worin das Peptid die Aminosäuresequenz Asn-Al a-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Cys
von dem Carboxyl terminus bis zum Aminoterminus besitzt.20. Conjugate according to claim 11, wherein the peptide has the amino acid sequence Asn-Al a-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Cys
from the carboxyl terminus to the amino terminus. 21. Konjugat nach Anspruch 20, worin das Peptid chemisch synthetisiert worden ist.21. The conjugate of claim 20, wherein the peptide has been chemically synthesized. 22. Konjugat nach Anspruch 18, worin das Peptid Tetanustoxoid ist.22. The conjugate of claim 18, wherein the peptide is tetanus toxoid. 23. Konjugat nach Anspruch 20, worin das Peptid Tetanustoxoid ist.23. The conjugate of claim 20, wherein the peptide is tetanus toxoid. 24. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 18.24. A vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 18. 25. Vakzinkomponente gegen den P.falciparum Malaria-Parasit, bestehend im wesentlichen aus dem Konjugat nach Anspruch 20.25. A vaccine component against the P.falciparum malaria parasite, consisting essentially of the conjugate according to claim 20. 26. Vakzin gegen das Sporozoitenstadium des P.falciparum Malarai-Parasits, umfassend ein Konjugat eines Peptids mit der Sequenz Cys-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro,
ein Trägerprotein und ein Vakzinhilfsmittel, wobei das Vakzin zum Immunisieren von Säugern geeignet ist.26. A vaccine against the sporozoite stage of the P.falciparum malaria parasite, comprising a conjugate of a peptide having the sequence Cys-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro,
a carrier protein and a vaccine adjuvant, the vaccine being suitable for immunising mammals.
DE1986902613 1985-03-28 1986-03-27 IMMUNOGENIC ANTIGEN-CARRIER PROTEIN CONJUGATE FOR USE IN VACCINE AGAINST MALARIA. Pending DE216901T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71696085A 1985-03-28 1985-03-28
PCT/US1986/000627 WO1986005790A1 (en) 1985-03-28 1986-03-27 Immunogenic antigen-carrier protein conjugate for use in a vaccine against malaria

Publications (1)

Publication Number Publication Date
DE216901T1 true DE216901T1 (en) 1987-07-23

Family

ID=26773520

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1986902613 Pending DE216901T1 (en) 1985-03-28 1986-03-27 IMMUNOGENIC ANTIGEN-CARRIER PROTEIN CONJUGATE FOR USE IN VACCINE AGAINST MALARIA.

Country Status (2)

Country Link
DE (1) DE216901T1 (en)
DK (1) DK570386D0 (en)

Also Published As

Publication number Publication date
DK570386A (en) 1986-11-27
DK570386D0 (en) 1986-11-27

Similar Documents

Publication Publication Date Title
DE69228698T2 (en) HYBRID PROTEIN BETWEEN PLASMODIUM AND HBsAG
US20060292170A1 (en) Vaccine Composition Against Malaria
Rutgers et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum.
DE69229107T2 (en) PEPTIDE SEQUENCES, SPECIFIC FOR THE HEPATITIC PHASE OF P. FALCIPARUM, WEARING EPITOPE; THAT HAVE THE ABILITY TO ENCOURAGE THE T LYMPHOCYTES
KR940000115A (en) Immune Carrier System for Gonadotropin Release Hormone (GnRH)
CA2053924A1 (en) Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
DE3686178T2 (en) MALARIA VACCINE.
US20060073171A1 (en) Vaccine composition against malaria
IE860846L (en) Immunogenic antigen-carrier protein conjugate for use in a¹vaccine against malaria
DE3687071T2 (en) MALARIA VACCINE.
DE69635077T2 (en) AGAINST MALARIA POLYPEPTIDIC MOLECULES FROM VORERTHROCYTARY STADIUM
Audibert et al. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens
DE216901T1 (en) IMMUNOGENIC ANTIGEN-CARRIER PROTEIN CONJUGATE FOR USE IN VACCINE AGAINST MALARIA.
Clough et al. Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative
ATE159172T1 (en) PEPTIDES AND THEIR USE
DE69133208T2 (en) FOUR-AMINO ACID EPITOP WITH PROTECTIVE AGAINST PLASMODIUM VIVAX MALARIA
US20110262469A1 (en) Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax
EP0241725B1 (en) Improvements in and relating to vaccines
DE69233271T2 (en) THERAPEUTIC AND PREVENTIVE VACCINE AGAINST HIV
MY103217A (en) Plasmodium falciparum merozoite antigen pertides
DE3851310D1 (en) Synthetic peptides showing immunological activity can be used to prepare a vaccination against malaria.
DE229829T1 (en) IMMUNOGENOUS PEPTIDANTANTIFICATE WITH PLASMODIUM VIVAX CIRCUMSPOROZOIT PROTEIN.
DE69014150T2 (en) Immunogen compounds and their use in the production of genetically unrestricted synthetic vaccines and in the immunoenzymatic determination of antisporozoid antibodies from Plasmodium malariae.
DE3723583A1 (en) POLYPEPTIDE USEFUL FOR THE PRODUCTION OF ANTIMALARIA VACCINES AND DIAGNOSTIC EQUIPMENT FOR DETECTING MALARIA DISEASES
DD259877A5 (en) A process for the preparation of a polypeptide for the prophylaxis of mammalian Plasmodium infections